# 39. Oxidant and nitrosative damage exceeds defense and repair

**Base judgment: 37.6%; skeptical–optimistic sensitivity: 6.1%–72.9%.** Subjective probabilities of the causal proposition below, not effect sizes. Decimal places only show arithmetic. Reviewed 13 September 2026. [Probability method](probability_method.md) · [Collection index](README.md).

## The causal claim and its scope

Diabetes produces damaging reactive oxygen/nitrogen exposure in the sensory-neuron unit that exceeds defenses and materially degrades axonal maintenance.

**Scope:** Default early type 2 DPN. This broad mechanism allows mitochondrial and nonmitochondrial sources and does not require the classical glucose-overload model.

**Causal role:** convergent chemical injury. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint.

## Reasoning from the biological requirements

Reactive species are normal signals. Damage requires a local production-versus-removal imbalance and attack on consequential molecular targets. NADPH oxidases, mitochondrial sources, inflammatory cells and nitric-oxide-derived chemistry can contribute; they are alternative sources. Protein nitration, lipid oxidation and DNA injury are possible targets, not simultaneous requirements. The damage must exceed repair before axon loss, and a reduction in staining after treatment cannot alone show that oxidation caused the loss.

## Probabilities of the necessary claims

Conditional prices are skeptical / base / optimistic. Each price after the first assumes *all earlier requirements are true*. Their order is an order for assessing joint belief, not necessarily a linear biological pathway. The cumulative column uses the base scenario. Temporal order, connected compartments and the causal prevention comparison are included in these requirements, without extra generic multipliers.

| # | Necessary claim | Conditional YES | Cumulative YES | Reason for this judgment |
|---|---|---:|---:|---|
| 1 | Diabetes increases injurious local reactive-species exposure before terminal loss. | 55 / **85** / 95% | 85.0% | Experimental chemistry is strong; human source/timing and cell context are less direct. |
| 2 | Exposure causes consequential molecular damage beyond antioxidant and repair capacity. | 50 / **80** / 95% | 68.0% | Markers can reflect harmless turnover or downstream debris. |
| 3 | This molecular damage impairs connected peptidergic axon maintenance. | 55 / **85** / 95% | 57.8% | Multiple structural animal perturbations support a causal bridge. |
| 4 | Removing the excess chemical injury would materially preserve early terminals. | 40 / **65** / 85% | 37.6% | Human selective intervention and attributable fraction remain uncertain. |

## Evidence that moves the judgment

- After 28 weeks of untreated diabetes in mice, four weeks of a peroxynitrite-decomposition catalyst improved IENFD, whereas a protein-nitration inhibitor improved some functional measures without the same structural result. This separates broad reactive-species injury from one marker/target class. [Stavniichuk et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24687457/).

- Diabetic adult sensory neurons showed axonal oxidative stress despite reduced mitochondrial-matrix superoxide, supporting alternative sources rather than proving all oxidants arise from glucose-overloaded mitochondria. [Chowdhury et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20876714/).

- The 460-person NATHAN 1 antioxidant trial missed its primary endpoint despite some secondary clinical benefits. It constrains broad therapeutic extrapolation without directly excluding a localized, early oxidant mechanism. [NATHAN 1](https://pmc.ncbi.nlm.nih.gov/articles/PMC3161301/).

## Why these odds and how uncertain they are

The broad chemical-injury proposition has multiple plausible inputs and experimental structural perturbations, giving it a higher price than a specific oxidant-source story. The human trial record and missing compartmental exposure prevent high certainty. Because the hypothesis is broad, its price should not be interpreted as evidence for any one NOX enzyme, NOS isoform or antioxidant drug.

The skeptical scenario treats much oxidative staining as a consequence and assumes effective local repair. The optimistic scenario assumes pre-loss molecular injury is a common convergence point. Nitric oxide can also support perfusion; eliminating it globally is not the counterfactual being priced.

Conditional inputs: base **[85, 80, 85, 65]%**; skeptical **[55, 50, 55, 40]%**; optimistic **[95, 95, 95, 85]%**. Products give the headline prices. The span measures sensitivity to these interpretations; it is not a statistical confidence interval.

**Numerical update example:** Public human-relevant evidence that local oxidative modifications precede and impair maintenance would strengthen requirement 2; preserved function despite the modifications would weaken it. Changing only requirement 2 from 80% to 95% raises the whole price to **44.6%**; reducing it to 30% lowers the price to **14.1%**. These are hypothetical evidence updates. Even resolving that one requirement with certainty would leave a complete price of 47.0% if the others stayed unchanged.

## Overlap and boundary

Overlaps [RAGE](04_rage_signaling.md), [oxLDL](09_oxidized_ldl.md), [inflammation](19_tnf_tlr4_inflammation.md), [PARP](28_parp_nad_depletion.md) and [ferroptosis](29_ferroptosis.md). These probabilities are not independent evidence votes.